Oreofe O. Odejide, MD, MPH

Oreofe O. Odejide, MD, MPH

Medical Oncology

Contact Information

Office Phone Number







Oreofe O. Odejide, MD, MPH

Dr. Odejide received her medical degree from Howard University. She completed postgraduate training in Internal Medicine at the Brigham and Women's Hospital, followed by a fellowship training in Hematology and Medical Oncology at the Dana-Farber/Partners CancerCare Program. She is currently a member of the DFCI Hematologic Malignancies staff as well as a member of the Division of Population Sciences.



Assistant Professor of Medicine, Harvard Medical School


Lymphoma Program
Stem Cell Transplantation
CNS Lymphoma Center

Clinical Interests

CAR T-cell therapy, Lymphoma

Board Certification

  • Hematology
  • Internal Medicine
  • Medical Oncology


  • Dana-Farber/Partners CancerCare, Hematology/Oncology


  • Brigham and Women's Hospital, Internal Medicine

Medical School

  • Howard University College of Medicine


    Outcomes Research, Health Services Research, Hematologic Malignancies

    The focus of my research is to understand patterns of care, comparative effectiveness of treatments, and quality of care for patients with hematologic malignancies, throughout the continuum of disease from diagnosis through the end of life (EOL). I am interested in developing targeted interventions to improve the quality of care for patients with hematologic malignancies.


      • Early palliative care perceptions by patients with cancer and primary caregivers: metaphorical language. BMJ Support Palliat Care. 2024 May 13. View in: Pubmed

      • Depression in patients with hematologic malignancies: The current landscape and future directions. Blood Rev. 2024 May; 65:101182. View in: Pubmed

      • A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan; 103(1):185-198. View in: Pubmed

      • Mortality among patients with diffuse large B-cell lymphoma and mental disorders: a population-based study. J Natl Cancer Inst. 2023 10 09; 115(10):1194-1203. View in: Pubmed

      • Perspectives on Transfusions for Hospice Patients With Blood Cancers: A Survey of Hospice Providers. J Pain Symptom Manage. 2024 Jan; 67(1):1-9. View in: Pubmed

      • Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023 09 12; 7(17):4748-4759. View in: Pubmed

      • Access to High-Quality Hospice Care in a For-Profit World. Oncologist. 2023 09 07; 28(9):743-745. View in: Pubmed

      • A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma. Blood. 2023 08 17; 142(7):621-628. View in: Pubmed

      • Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study. Lancet Haematol. 2023 Jul; 10(7):e530-e538. View in: Pubmed

      • Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma. Hemasphere. 2023 Feb; 7(2):e826. View in: Pubmed

      • Perceptions of Death Among Patients with Advanced Cancer Receiving Early Palliative Care and Their Caregivers: Results from a Mixed-Method Analysis. Oncologist. 2023 01 18; 28(1):e54-e62. View in: Pubmed

      • Sequencing therapy in relapsed DLBCL. Hematology Am Soc Hematol Educ Program. 2022 12 09; 2022(1):146-154. View in: Pubmed

      • Patient, Family, and Clinician Perspectives on Location of Death for Adolescents and Young Adults With Cancer. JCO Oncol Pract. 2022 10; 18(10):e1621-e1629. View in: Pubmed

      • Correlates of common concerns in older cancer survivors of leukemia and lymphoma: results from the WHI LILAC study. J Cancer Surviv. 2023 06; 17(3):769-780. View in: Pubmed

      • Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma. 2022 12; 63(12):2912-2917. View in: Pubmed

      • Perceptions of Hope Among Bereaved Caregivers of Cancer Patients Who Received Early Palliative Care: A Content and Lexicographic Analysis. Oncologist. 2022 03 04; 27(2):e168-e175. View in: Pubmed

      • Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States. Blood Adv. 2022 02 22; 6(4):1126-1136. View in: Pubmed

      • A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia. 2022 03; 36(3):723-732. View in: Pubmed

      • End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma. J Palliat Med. 2022 05; 25(5):728-733. View in: Pubmed

      • Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplant Cell Ther. 2022 01; 28(1):32.e1-32.e10. View in: Pubmed

      • Changes in Cancer Patients' and Caregivers' Disease Perceptions While Receiving Early Palliative Care: A Qualitative and Quantitative Analysis. Oncologist. 2021 12; 26(12):e2274-e2287. View in: Pubmed

      • Prognostic value of disease risk score versus gait speed in older adults with lymphoma. Leuk Lymphoma. 2021 12; 62(12):2882-2889. View in: Pubmed

      • Prevalence and Tolerance of Prognostic Uncertainty Among Thoracic Oncologists. Oncologist. 2021 08; 26(8):e1480-e1482. View in: Pubmed

      • Goal of a "Good Death" in End-of-Life Care for Patients with Hematologic Malignancies-Are We Close? Curr Hematol Malig Rep. 2021 04; 16(2):117-125. View in: Pubmed

      • Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):148-153. View in: Pubmed

      • Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment. Cancer. 2021 03 15; 127(6):875-883. View in: Pubmed

      • A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. Leukemia. 2021 04; 35(4):1064-1072. View in: Pubmed

      • Patients with haematological malignancies should not have to choose between transfusions and hospice care. Lancet Haematol. 2020 May; 7(5):e418-e424. View in: Pubmed

      • Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867. View in: Pubmed

      • Perspectives Regarding Hospice Services and Transfusion Access: Focus Groups With Blood Cancer Patients and Bereaved Caregivers. J Pain Symptom Manage. 2020 06; 59(6):1195-1203.e4. View in: Pubmed

      • Goals of care discussions for patients with blood cancers: Association of person, place, and time with end-of-life care utilization. Cancer. 2020 02 01; 126(3):515-522. View in: Pubmed

      • PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29. View in: Pubmed

      • How Do Blood Cancer Doctors Discuss Prognosis? Findings from a National Survey of Hematologic Oncologists. J Palliat Med. 2019 06; 22(6):677-684. View in: Pubmed

      • Meaningful changes in end-of-life care among patients with myeloma. Haematologica. 2018 08; 103(8):1380-1389. View in: Pubmed

      • Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival. Cancer Epidemiol Biomarkers Prev. 2018 03; 27(3):345-347. View in: Pubmed

      • Septic Episodes in a Premature Infant After In Utero Exposure to Rituximab. Pediatrics. 2017 Sep; 140(3). View in: Pubmed

      • Why are patients with blood cancers more likely to die without hospice? Cancer. 2017 Sep 01; 123(17):3377-3384. View in: Pubmed

      • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. View in: Pubmed

      • Barriers to Quality End-of-Life Care for Patients With Blood Cancers. J Clin Oncol. 2016 09 10; 34(26):3126-32. View in: Pubmed

      • Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 08; 22(8):1504-1510. View in: Pubmed

      • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. View in: Pubmed

      • Novel Data Sharing Between a Comprehensive Cancer Center and a Private Payer to Better Understand Care at the End of Life. J Pain Symptom Manage. 2016 08; 52(2):161-9. View in: Pubmed

      • Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes. Br J Haematol. 2016 06; 173(5):713-21. View in: Pubmed

      • Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer. 2016 Apr 15; 122(8):1209-15. View in: Pubmed

      • Timeliness of End-of-Life Discussions for Blood Cancers: A National Survey of Hematologic Oncologists. JAMA Intern Med. 2016 Feb; 176(2):263-5. View in: Pubmed

      • A Policy Prescription for Hospice Care. JAMA. 2016 Jan 19; 315(3):257-8. View in: Pubmed

      • Hospice Use Among Patients With Lymphoma: Impact of Disease Aggressiveness and Curability. J Natl Cancer Inst. 2016 Jan; 108(1). View in: Pubmed

      • Novel data sharing between a comprehensive cancer center and a private payer to better understand care at the end of life. J Clin Oncol. 2014 Oct 20; 32(30_suppl):1. View in: Pubmed

      • End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract. 2014 Nov; 10(6):e396-403. View in: Pubmed

      • Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica. 2014 Sep; 99(9):1421-32. View in: Pubmed

      • Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma. 2015 Mar; 56(3):716-24. View in: Pubmed

      • Reply to quality control of bone marrow aspirates: additional steps toward a safer and more efficient procedure. Cancer. 2014 May 01; 120(9):1442. View in: Pubmed

      • A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014 Feb 27; 123(9):1293-6. View in: Pubmed

      • Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist. Cancer. 2013 Oct 01; 119(19):3472-8. View in: Pubmed

      • Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 2013 Apr; 27(4):968-71. View in: Pubmed

      • An extreme example of focal bone marrow involvement in acute myeloid leukemia. Am J Hematol. 2013 Apr; 88(4):335-6. View in: Pubmed

      • Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer. Clin Colorectal Cancer. 2013 Mar; 12(1):62-9. View in: Pubmed

      • Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report. Anticancer Res. 2012 May; 32(5):1743-6. View in: Pubmed


      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      Oreofe O. Odejide, MD, MPH

      About Our Ratings

      Physician Star Rating Comment Block